PharmExec articleshttps://www.pharmexec.com/newsPharmExec articles© 2026 MJH Life Sciences™ and PharmExec. All rights reserved.Mon, 28 Sep 2026 14:58:38 +00005en-us14447https://www.pharmexec.com/newshttps://www.pharmexec.com/logo.webphttps://www.pharmexec.com/view/compounding-crossroads-safety-standards-industry-best-defensehttps://www.pharmexec.com/view/compounding-crossroads-safety-standards-industry-best-defense<![CDATA[Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.]]>Mon, 28 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/your-questions-answered-two-fda-approvals-six-platform-deals-and-aeuropean-warninghttps://www.pharmexec.com/view/your-questions-answered-two-fda-approvals-six-platform-deals-and-aeuropean-warning<![CDATA[Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.]]>Mon, 28 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/consolidation-can-improve-digital-employer-covered-healthcare-platformshttps://www.pharmexec.com/view/consolidation-can-improve-digital-employer-covered-healthcare-platforms<![CDATA[Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.]]>Mon, 28 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/why-early-big-picture-planning-is-key-to-execution-across-the-cgt-lifecyclehttps://www.pharmexec.com/view/why-early-big-picture-planning-is-key-to-execution-across-the-cgt-lifecycle<![CDATA[Learn how early regulatory, evidence, manufacturing, and EU access planning keeps CGT launches on track, from CoI logistics to payer coverage.]]>Fri, 25 Sep 2026 20:31:36 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fda-approves-welireg-lenvimahttps://www.pharmexec.com/view/daily-fda-approves-welireg-lenvima<![CDATA[FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.]]>Fri, 25 Sep 2026 17:54:03 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/from-content-factory-to-content-intelligence-why-pharmas-next-competitive-advantage-is-making-content-matterhttps://www.pharmexec.com/view/from-content-factory-to-content-intelligence-why-pharmas-next-competitive-advantage-is-making-content-matter<![CDATA[For more than a decade, pharmaceutical organisations have invested heavily in solving one fundamental challenge: how to produce more high-quality content, more efficiently, across an ever-expanding number of channels. Yet despite these advances, an important question remains: has greater productivity translated into greater impact?]]>Fri, 25 Sep 2026 14:40:29 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-approves-welireg-plus-lenvima-adult-patients-ccrcchttps://www.pharmexec.com/view/fda-approves-welireg-plus-lenvima-adult-patients-ccrcc<![CDATA[FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma. ]]>Fri, 25 Sep 2026 13:50:22 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/-nanexa-earendil-labs-atavistik-bio-enter-platform-deals-novo-genentech-rochehttps://www.pharmexec.com/view/-nanexa-earendil-labs-atavistik-bio-enter-platform-deals-novo-genentech-roche<![CDATA[Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.]]>Fri, 25 Sep 2026 13:21:15 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/rutledge-congress-regulate-pharmacy-benefit-managershttps://www.pharmexec.com/view/rutledge-congress-regulate-pharmacy-benefit-managers<![CDATA[Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.]]>Fri, 25 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/oral-l-glutamine-could-be-pancreatic-cancer-most-accessible-treatment-advance-dr-jun-gong-mdhttps://www.pharmexec.com/view/oral-l-glutamine-could-be-pancreatic-cancer-most-accessible-treatment-advance-dr-jun-gong-md<![CDATA[Adding oral L-glutamine to standard chemo nearly tripled median OS in advanced pancreatic cancer — and what comes next.]]>Fri, 25 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/factors-driving-employer-healthcare-costs-higherhttps://www.pharmexec.com/view/factors-driving-employer-healthcare-costs-higher<![CDATA[Numerof's Michael Abrams on why healthcare consolidation is the primary driver of rising employer costs — and why there's no end in sight.]]>Fri, 25 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fda-approves-onswikhttps://www.pharmexec.com/view/daily-fda-approves-onswik<![CDATA[InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.]]>Thu, 24 Sep 2026 17:46:44 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/innocare-3-billion-research-collaboration-license-agreement-eli-lillyhttps://www.pharmexec.com/view/innocare-3-billion-research-collaboration-license-agreement-eli-lilly<![CDATA[Eli Lilly is set to pay InnoCare Pharma up to $3.35 billion to discover and develop compounds against upwards of five undisclosed targets. ]]>Thu, 24 Sep 2026 13:50:07 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-approves-onswik-adults-type-2-diabeteshttps://www.pharmexec.com/view/fda-approves-onswik-adults-type-2-diabetes<![CDATA[FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes. ]]>Thu, 24 Sep 2026 13:23:16 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/clinical-trial-enrolling-right-patients-jen-lamppahttps://www.pharmexec.com/view/clinical-trial-enrolling-right-patients-jen-lamppa<![CDATA[Why self-reported data fails clinical trials — and how RWD and AI fix enrollment accuracy before the first patient is dosed.]]>Thu, 24 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/what-actually-went-wrong-when-phase-3-trial-fails-dr-remo-moomiaie-qajarhttps://www.pharmexec.com/view/what-actually-went-wrong-when-phase-3-trial-fails-dr-remo-moomiaie-qajar<![CDATA[Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures.]]>Thu, 24 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/the-healthcare-insight-gap-why-generic-ai-falls-short-and-what-healthcare-marketers-need-insteadhttps://www.pharmexec.com/view/the-healthcare-insight-gap-why-generic-ai-falls-short-and-what-healthcare-marketers-need-instead<![CDATA[How Human-Led, AI-Powered systems designed specifically for healthcare turn data overload into decision-ready insight. Healthcare marketers are flooded with data, from patient conversations and HCP feedback to social listening, CRM activity, and market signals, yet actionable insights remain difficult to uncover. This eBook explores why generic AI often falls short in healthcare and shows how a Human-Led, AI-Powered approach can turn complex data into trusted, decision-ready intelligence.]]>Thu, 24 Sep 2026 04:27:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/-daily-mike-doustdar-open-direct-listing-novo-shareshttps://www.pharmexec.com/view/-daily-mike-doustdar-open-direct-listing-novo-shares<![CDATA[EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.]]>Wed, 23 Sep 2026 17:23:37 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/novo-ceo-considering-direct-shares-listing-reporthttps://www.pharmexec.com/view/novo-ceo-considering-direct-shares-listing-report<![CDATA[Novo Nordisk CEO Mike Doustdar says he's open to a direct NYSE listing that would replace the company's ADR structure. ]]>Wed, 23 Sep 2026 14:03:22 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/shaping-future-market-access-jen-nortonhttps://www.pharmexec.com/view/shaping-future-market-access-jen-norton<![CDATA[Market access is now too complex for historical analogues — and AI is the only tool that can model what comes next.]]>Wed, 23 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/strategic-ai-adoption-clinical-data-harmonization-life-scienceshttps://www.pharmexec.com/view/strategic-ai-adoption-clinical-data-harmonization-life-sciences<![CDATA[Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential.]]>Wed, 23 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/ai-being-used-prevent-clinical-trial-mismatcheshttps://www.pharmexec.com/view/ai-being-used-prevent-clinical-trial-mismatches<![CDATA[Inovalon's Jen Lamppa on why AI's ability to extract insights from unstructured clinical data is foundational to making RWD usable in trials.]]>Wed, 23 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-european-drugmakers-concern-region-investmentshttps://www.pharmexec.com/view/daily-european-drugmakers-concern-region-investments<![CDATA[Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat Rahmani argues that the costliest competitive intelligence failure is missing the moment a strategic assumption goes wrong.]]>Tue, 22 Sep 2026 18:51:01 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/most-expensive-ci-failure-missing-moment-strategic-assumption-became-wronghttps://www.pharmexec.com/view/most-expensive-ci-failure-missing-moment-strategic-assumption-became-wrong<![CDATA[The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.]]>Tue, 22 Sep 2026 17:54:32 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/nine-european-drugmakers-warn-losing-pharma-investmenthttps://www.pharmexec.com/view/nine-european-drugmakers-warn-losing-pharma-investment<![CDATA[Chairs of Europe's largest drugmakers urge the EU to boost health spending, speed up clinical trials, and strengthen IP protections before falling further behind the US and China.]]>Tue, 22 Sep 2026 16:31:03 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/clarity-in-compliancehttps://www.pharmexec.com/view/clarity-in-compliance<![CDATA[How to efficiently and accurately plan for and comply with aggregate spend, drug price transparency laws, and government price reporting requirements.]]>Tue, 22 Sep 2026 14:24:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/novartis-boomray-global-license-agreement-preclinical-radioligand-assethttps://www.pharmexec.com/view/novartis-boomray-global-license-agreement-preclinical-radioligand-asset<![CDATA[Novartis has agreed to pay BoomRay up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset.]]>Tue, 22 Sep 2026 13:40:12 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/how-recent-fda-actions-impact-sponsorshttps://www.pharmexec.com/view/how-recent-fda-actions-impact-sponsors<![CDATA[Inovalon's Jen Lamppa on why FDA's acceptance of RWD downstream is a call to action for sponsors to start using it upstream in trial design.]]>Tue, 22 Sep 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-abbvie-ai-powered-drug-discovery-partnership-lambichttps://www.pharmexec.com/view/daily-abbvie-ai-powered-drug-discovery-partnership-lambic<![CDATA[AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.]]>Mon, 21 Sep 2026 18:20:02 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/-abbvie-lambic-ai-drug-discovery-telix-merges-itmhttps://www.pharmexec.com/view/-abbvie-lambic-ai-drug-discovery-telix-merges-itm<![CDATA[AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM. ]]>Mon, 21 Sep 2026 14:14:29 GMTPharmExecusPharmExec Articles